Researchers reveal secondary structure of Lewy bodies in the brain of Parkinson's disease patients

NewsGuard 100/100 Score

Lewy bodies had been considered to be a key element of pathogenesis for Parkinson's disease. Although structural analysis for Lewy bodies with an electron microscope had been performed, it had no secondary structural information of proteins, which is important for the development of drugs. A research group led by Osaka University succeeded in elucidating the secondary structure of Lewy bodies in the brain of Parkinson's disease patients for the first time with synchrotron Fourier transform infrared micro-spectroscopy.

A group of researchers at Osaka University in cooperation with the Japan Synchrotron Radiation Research Institute (JASRI), succeeded in elucidating the secondary structure of Lewy bodies in the brain of Parkinson's disease patients for the first time with synchrotron Fourier transform infrared micro-spectroscopy (FTIRM).

Lewy bodies had been considered to be a key element of pathogenesis for Parkinson's disease. Although structural analysis for Lewy bodies with an electron microscope had been performed, it had no secondary structural information of proteins, which is important for the development of drugs.

In recent years, many researchers have focused on new treatment to inhibit the formation of abnormal protein aggregates, which can delay the onset and progression of Parkinson's disease. The results and methods of this research may provide important clues to the development of epoch-making treatment for Parkinson's disease.

Parkinson's disease is the most common progressive neurodegenerative disorder after Alzheimer's disease, and there is no basic treatment to control the development of the disease. It had been known for quite some time that Lewy bodies, abnormal protein aggregates, are formed in the brain of Parkinson's disease patients, and it is thought that Lewy bodies play an important role in the onset of the disease. However, the structural analysis of Lewy bodies has made no progress other than observation with an electronic microscope in the last 20 years. Information on proteins required for developing treatment drugs has been unavailable from electron microscopic observation.

A group of researchers led by Hideki Mochizuki, Professor and Katsuya Araki, Clinical Fellow at the Department of Neurology, Graduate School of Medicine, Osaka University, in cooperation with Dr. Naoto Yagi, JASRI, analyzed proteins by synchrotron Fourier transform infrared micro-spectroscopy with the infrared beamline BL43IR at the SPring-8 synchrotron radiation facility and succeeded in obtaining structural information which had not been obtained from the electronic microscopy.

In experiments by this group, it was necessary to make measurements while irradiating infrared beams of a few micrometers in diameter on a Lewy body of with a 10 micrometer diameter. For that purpose, radiation light at the SPring-8, the brightest in the world, played a great role.

The experiment showed that Lewy bodies in the brain of Parkinson's disease patients had many β sheet structures. This supports the validity of in-vitro studies in the past. It was also found that the rate of β sheet structures was higher in the halo of a Lewy body than in the core of a Lewy body and the core was lipid-rich. These findings will lead to the elucidation of the mystery of the formation of Lewy bodies.

This research was featured in the electronic version of Scientific Reports on Tuesday, December 1, 2015.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough brain stimulator could revolutionize treatment for neurological disorders